top of page
our pipeline
The discovery platform is key to a growing pipeline of novel candidate compounds. Our current portfolio focuses on solid cancers, which represent about 90 percent of adult cancer cases.
-
Seven novel candidate compounds shown to inhibit SERCA;
-
Candidates show powerful anti-cancer effects through combination treatment with standard cancer therapies;
-
Active ongoing research on candidate compounds for stand-alone therapeutic drugs on refractory cancers.

our platform
Our scientific team combines our proprietary drug discovery platform with a PDC / PDX (Patient Derived Cell / Patient Derived Xenograft) model platform to discover candidate compounds for new drugs aimed specifically at refractory advanced cancers.
Combination treatment effect with C19, C23

bottom of page